Lund-based MedVasc has raised €2.2 million by means of subscriptions solely from present shareholders, in addition to finishing manufacturing and testing actions for his or her anesthesia catheter Solutio, advancing towards FDA clearance.
This follows Could 2025’s €917k financing spherical, as covered by EU-Startups.
”The sturdy participation from present homeowners demonstrates continued confidence in MedVasc’s technique, execution functionality, and long-term worth creation. The board and administration view this assist as a transparent validation of the corporate’s path and its ongoing improvement efforts,” says Cathrin Johansson, CEO of MedVasc.
Evaluation of 2025–2026 exhibits continued funding exercise throughout European MedTech and adjoining HealthTech segments, offering context for MedVasc’s shareholder-backed increase.
Bigger later-stage rounds embody ProVerum (Eire), which secured €68.6 million to advance a minimally invasive urology remedy, and SamanTree Medical (Belgium), which obtained €20 million from the European Funding Financial institution to assist real-time surgical imaging expertise.
Mid-range rounds embody ShanX Medtech (Netherlands), which raised a mixed €24 million to deal with antimicrobial resistance, and PIUR IMAGING (Austria), which secured €5.6 million to scale its 3D ultrasound imaging platform.
On the earlier stage, Ahead Health (Switzerland) raised €5.1 million for preventive healthcare providers, and Doctor.One (Poland) raised €4 million to develop its persistent care mannequin.
Collectively, these rounds signify roughly €130 million in disclosed funding flowing by means of European MedTech and HealthTech throughout this era. In opposition to this backdrop, MedVasc’s financing is modest in dimension however according to early-stage European medical machine firms centered on finishing manufacturing, validation, and regulatory milestones forward of business enlargement.
MedVasc AB was based in 2013 by Michael Åkesson; a senior marketing consultant of interventional radiology with expertise of over twenty years with catheter primarily based remedies and prognosis. Beforehand he was the Head of the Division of Endovascular Surgical procedure on the Vascular Division, College Hospital SUS Malmö. He now works as a senior marketing consultant on the Scandinavian Venous Centre, Malmö.
He’s the principle proprietor of MedVASC AB and the inventor behind Solutio.
MedVasc can be taking part in SmiLe’s incubator programme – additionally primarily based in Lund. SmiLe is a enterprise hub that specialises in advancing life science and FoodTech startups from idea to commercialisation. So far, their flagship incubator programme has supported over 110 startups, facilitating their collective acquisition of greater than €1.05 billion in enterprise capital and contributing to 21 profitable IPOs.
The corporate has developed and patented the medical machine Solutio, designed to enhance the anaesthetic process when treating varicose veins.
Solutio is designed to allow protected and exact native anesthesia throughout minimally invasive vascular procedures, e.g. varicose veins, (appropriate with thermal ablation remedy fibers), providing a brand new stage of management and affected person consolation for clinicians treating persistent venous issues.
It was developed to supply painless and exact native anesthesia throughout thermal remedy of venous insufficiency. The anesthesia catheter is appropriate with so-called gold customary remedy fibers (RF/Laser) worldwide.
With the financing secured, MedVasc is effectively positioned to speed up the remaining key actions required for FDA clearance of Solutio for the U.S. market. Preparations are progressing based on plan, and market approval is anticipated throughout autumn 2026.
